Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on th...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Michelle McMullen, Katherine Karakasis, Ainhoa Madariaga, Amit M. Oza
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2020-06-01
Cyfres:Cancers
Pynciau:
resistance mechanisms
platinum
PARP
ovarian cancer
homologous recombination
Mynediad Ar-lein:https://www.mdpi.com/2072-6694/12/6/1607
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg